![Blake Scott](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profilo
Dr. Blake Scott is a Vice President & Research Analyst at Aquilo Capital Management LLC.
Dr. Scott joined McKinsey & Co.’s New York office as a management consultant.
He served a range of pharmaceutical clients, including projects on regulatory, commercial, and R&D considerations.
He supported diligence on immuno-oncology portfolios, assets, biotechnology partnerships, and overall research strategies.
He helped develop strategies to improve clinical trial design and oversight for oncology trials, and supported the management in large mergers and acquisitions in the pharmaceutical space.
Dr. Scott completed his PhD in Cellular and Molecular Medicine at the Johns Hopkins School of Medicine,
Precedenti posizioni note di Blake Scott
| Società | Posizione | Fine |
|---|---|---|
Aquilo Capital Management LLC
 Aquilo Capital Management LLC Investment ManagersFinance Aquilo manages funds that generally focus on the life sciences industry, with a specific focus on biotechnology and drug discovery and development companies. The firm employs deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. Their goal is to provide long- term clients and investors with a high rate of return relative to risk over time. | Analyst-Equity | 01/11/2022 |
Formazione di Blake Scott
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
1
Relazioni di 1° grado
2
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Aquilo Capital Management LLC
Aquilo Capital Management LLC Investment ManagersFinance Aquilo manages funds that generally focus on the life sciences industry, with a specific focus on biotechnology and drug discovery and development companies. The firm employs deep sector expertise and a disciplined, value-oriented process to identify extraordinary biotech companies with the potential to alter the practice of medicine in profound ways. Their goal is to provide long- term clients and investors with a high rate of return relative to risk over time. | Finance |
The Johns Hopkins University School of Medicine
 The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
